Tandem Diabetes Care (TNDM) Cost of Revenue (2013 - 2026)

Tandem Diabetes Care (TNDM) has 14 years of Cost of Revenue data on file, last reported at $110.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 4.81% year-over-year to $110.4 million; the trailing twelve-month figure through Mar 2026 stood at $463.1 million (down 1.38% YoY), and the FY2025 full-year result was $468.7 million, up 4.02% from the prior year.
• Cost of Revenue for Q1 2026 stood at $110.4 million, down from $122.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $125.2 million in Q4 2024 and bottomed at $84.8 million in Q1 2022.
• The 5-year median for Cost of Revenue is $105.0 million (2022), against an average of $105.8 million.
• The widest annual swing landed in 2022, when Cost of Revenue increased 25.19%; it then declined 4.81% in 2026.
• A 5-year view of Cost of Revenue shows it stood at $105.0 million in 2022, then retreated by 1.41% to $103.5 million in 2023, then gained by 20.96% to $125.2 million in 2024, then declined by 1.81% to $122.9 million in 2025, then dropped by 10.16% to $110.4 million in 2026.
• The last three Cost of Revenue figures came in at $110.4 million (Q1 2026), $122.9 million (Q4 2025), and $115.0 million (Q3 2025), per Business Quant data.

Peer Comparison